Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al
- PMID: 28478402
- DOI: 10.1136/annrheumdis-2017-211455
Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al
Keywords: DMARDs (synthetic); rheumatoid arthritis; treatment.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Review.
-
2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?Ann Rheum Dis. 2017 Nov;76(11):e47. doi: 10.1136/annrheumdis-2017-211446. Epub 2017 Mar 27. Ann Rheum Dis. 2017. PMID: 28347992 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical